A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern

Numerous vaccines have been developed to address the current COVID-19 pandemic, but safety, cross-neutralizing efficacy, and long-term protectivity of currently approved vaccines are still important issues. In this study, we developed a subunit vaccine, ASD254, by using a nanoparticle vaccine platfo...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, I-Jung, Lan, Yu-Hua, Wu, Ping-Yi, Wu, Yan-Wei, Chen, Yu-Hung, Tseng, Sheng-Che, Kuo, Tzu-Jiun, Sun, Cheng-Pu, Jan, Jia-Tsrong, Ma, Hsiu-Hua, Liao, Chun-Che, Liang, Jian-Jong, Ko, Hui-Ying, Chang, Chih-Shin, Liu, Wen-Chun, Ko, Yi-An, Chen, Yen-Hui, Sie, Zong-Lin, Tsung, Szu-I, Lin, Yi-Ling, Wang, I-Hsuan, Tao, Mi-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Coronaviruses
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793938/
https://www.ncbi.nlm.nih.gov/pubmed/36395071
http://dx.doi.org/10.1080/22221751.2022.2149353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793938/
https://www.ncbi.nlm.nih.gov/pubmed/36395071
http://dx.doi.org/10.1080/22221751.2022.2149353

Ejemplares similares